Business Description
Rigel Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US7665596034
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.94 | |||||
Equity-to-Asset | -0.24 | |||||
Debt-to-Equity | -2.12 | |||||
Debt-to-EBITDA | -3.57 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -15.06 | |||||
Beneish M-Score | -3.46 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.4 | |||||
3-Year EBITDA Growth Rate | 15.8 | |||||
3-Year EPS without NRI Growth Rate | 8 | |||||
3-Year FCF Growth Rate | 27.9 | |||||
Future 3-5Y Total Revenue Growth Rate | 24.94 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 34.51 | |||||
9-Day RSI | 32.57 | |||||
14-Day RSI | 34.8 | |||||
6-1 Month Momentum % | 91.19 | |||||
12-1 Month Momentum % | 24.02 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.86 | |||||
Quick Ratio | 1.76 | |||||
Cash Ratio | 1.07 | |||||
Days Inventory | 437.5 | |||||
Days Sales Outstanding | 90.31 | |||||
Days Payable | 504.98 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.1 | |||||
Shareholder Yield % | -10.97 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 93.92 | |||||
Operating Margin % | -17.53 | |||||
Net Margin % | -21.47 | |||||
FCF Margin % | -17.75 | |||||
ROA % | -20.65 | |||||
ROIC % | -42.22 | |||||
ROC (Joel Greenblatt) % | -837.19 | |||||
ROCE % | -25.94 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.66 | |||||
EV-to-EBIT | -10.79 | |||||
EV-to-Forward-EBIT | -13.11 | |||||
EV-to-EBITDA | -11.58 | |||||
EV-to-Forward-EBITDA | -13.11 | |||||
EV-to-Revenue | 1.68 | |||||
EV-to-Forward-Revenue | 1.44 | |||||
EV-to-FCF | -9.48 | |||||
Price-to-Median-PS-Value | 0.24 | |||||
Earnings Yield (Greenblatt) % | -9.27 | |||||
FCF Yield % | -10.75 |